Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURANASDAQ:IZTCNASDAQ:RCKTNASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.40-0.3%$5.76$4.35▼$12.38$321.72M0.42210,318 shs184,834 shsIZTCInvizyne Technologies$12.81-2.6%$12.59$8.50▼$23.00$80.09MN/A37,647 shs166 shsRCKTRocket Pharmaceuticals$2.88-1.7%$5.55$2.19▼$26.98$307.54M0.683.34 million shs4.00 million shsSNDLSNDL$1.33+3.1%$1.34$1.24▼$2.40$349.49M3.451.97 million shs1.12 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences0.00%-1.23%+7.90%-14.85%-12.41%IZTCInvizyne Technologies0.00%-4.66%-5.50%-16.55%+1,280,999,900.00%RCKTRocket Pharmaceuticals0.00%-4.56%-54.92%-66.82%-86.60%SNDLSNDL0.00%-2.27%-4.44%-16.77%-33.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.6902 of 5 stars3.61.00.00.03.83.30.0IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ARCKTRocket Pharmaceuticals4.9476 of 5 stars4.24.00.04.72.95.01.3SNDLSNDL3.722 of 5 stars3.55.00.00.02.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.00243.75% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ARCKTRocket Pharmaceuticals 2.41Hold$19.57579.56% UpsideSNDLSNDL 3.00Buy$3.63172.56% UpsideCurrent Analyst Ratings BreakdownLatest IZTC, SNDL, RCKT, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $11.005/30/2025RCKTRocket PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ In-Line$5.005/28/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/28/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/28/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $9.005/28/2025RCKTRocket PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $8.005/28/2025RCKTRocket PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $19.005/28/2025RCKTRocket PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Sell5/28/2025RCKTRocket PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$37.00 ➝ $8.005/28/2025RCKTRocket PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$7.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.46 per shareN/ASNDLSNDL$927.61M0.38N/AN/A$3.47 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$76.41M-$1.90N/AN/AN/AN/A-41.57%-36.43%8/8/2025 (Estimated)IZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ARCKTRocket Pharmaceuticals-$245.60M-$2.63N/AN/AN/AN/A-62.62%-54.17%8/4/2025 (Estimated)SNDLSNDL-$127.91M-$0.29N/AN/AN/A-12.11%-8.27%-6.96%7/30/2025 (Estimated)Latest IZTC, SNDL, RCKT, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A5/1/2025Q1 2025SNDLSNDL-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.4712.47IZTCInvizyne TechnologiesN/AN/AN/ARCKTRocket Pharmaceuticals0.066.056.05SNDLSNDL0.105.614.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%IZTCInvizyne TechnologiesN/ARCKTRocket Pharmaceuticals98.39%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%IZTCInvizyne TechnologiesN/ARCKTRocket Pharmaceuticals24.76%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.25 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/ARCKTRocket Pharmaceuticals240106.79 million65.18 millionOptionableSNDLSNDL580262.78 millionN/AOptionableIZTC, SNDL, RCKT, and AURA HeadlinesRecent News About These CompaniesHYTN Receives Initial International Purchase Order for GMP Vape CartridgesJune 11, 2025 | finance.yahoo.comMarijuana Stocks To Watch With Strong Market PotentialJune 6, 2025 | marijuanastocks.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 612,495 Shares of SNDL Inc. (NASDAQ:SNDL)May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in SNDL Inc. (NASDAQ:SNDL)May 21, 2025 | marketbeat.com1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court OrderMay 20, 2025 | finance.yahoo.comCanadian Securities Exchange Reports April 2025 Performance FiguresMay 15, 2025 | finance.yahoo.comSA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLIMay 5, 2025 | msn.comSNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has IncreasedMay 5, 2025 | seekingalpha.comSNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call TranscriptMay 3, 2025 | insidermonkey.comSNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2025 | finance.yahoo.com3 Marijuana Stocks For The Long Term InvestingMay 2, 2025 | marijuanastocks.comSNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market ReviewMay 2, 2025 | uk.finance.yahoo.comThese Cannabis Companies Are Repurchasing SharesMay 2, 2025 | newcannabisventures.comSNDL Inc. (SNDL) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comSNDL 1Q Loss WidensMay 2, 2025 | marketwatch.comSNDL Inc. Earnings Call Highlights Growth and ChallengesMay 1, 2025 | tipranks.comSNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue EstimatesMay 1, 2025 | zacks.comSNDL Reports Record Q1 2025 Results and Strategic InitiativesMay 1, 2025 | tipranks.comSNDL Reports First Quarter 2025 Financial and Operational ResultsMay 1, 2025 | prnewswire.comSNDL Launches Rise Rewards Loyalty ProgramApril 22, 2025 | prnewswire.comSNDL Inc. to Acquire 32 Cannabis Retail Stores in Strategic ExpansionApril 17, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIZTC, SNDL, RCKT, and AURA Company DescriptionsAura Biosciences NASDAQ:AURA$6.40 -0.02 (-0.31%) Closing price 04:00 PM EasternExtended Trading$6.40 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Invizyne Technologies NASDAQ:IZTC$12.81 -0.34 (-2.59%) As of 06/13/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Rocket Pharmaceuticals NASDAQ:RCKT$2.88 -0.05 (-1.71%) Closing price 04:00 PM EasternExtended Trading$2.88 0.00 (0.00%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.SNDL NASDAQ:SNDL$1.33 +0.04 (+3.10%) Closing price 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
